Cafestol overcomes ABT-737 resistance in Mcl-1-overexpressed renal carcinoma Caki cells through downregulation of Mcl-1 expression and upregulation of Bim expression

Cell Death and Disease

Volumn 5, Issue 11, 2014, Pages

  Woo, S M ^a   Min, K J ^a   Seo, B R ^a   Nam, J O ^b   Choi, K S ^c   Yoo, Y H ^d   Kwon, T K ^a  

^a Keimyung University   (South Korea)

^b Kyungpook National University   (South Korea)

^c Ajou University School of Medicine   (South Korea)

^d Dong A University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BIM PROTEIN; CAFESTOL; CASPASE 3; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BCL XL; PROTEIN MCL 1; SMALL INTERFERING RNA; ABT-737; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; BCL-2-LIKE PROTEIN 11; BIPHENYL DERIVATIVE; DITERPENE; MCL1 PROTEIN, HUMAN; MEMBRANE PROTEIN; NITROPHENOL; ONCOPROTEIN; PIPERAZINE DERIVATIVE; SULFONAMIDE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CELL DEATH; CELL STRUCTURE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME ACTIVITY; GLIOMA CELL LINE; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; LONG TERM SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN FIBROBLAST; TUMOR XENOGRAFT; UPREGULATION; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, RENAL CELL; COMBINATION DRUG THERAPY; CYTOLOGY; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; FIBROBLAST; GENE EXPRESSION REGULATION; GENETICS; KIDNEY NEOPLASMS; MALE; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BIPHENYL COMPOUNDS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; DITERPENES; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MALE; MEMBRANE PROTEINS; MICE; MICE, NUDE; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NITROPHENOLS; PIPERAZINES; PRIMARY CELL CULTURE; PROTO-ONCOGENE PROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84927939215     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.472     Document Type: Article

References (42)

1. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 family reunion. Mol Cell 2010; 37: 299-310.
2. Lomonosova E, Chinnadurai G. BH3-only proteins in apoptosis and beyond: an overview. Oncogene 2008; 27 (Suppl 1): S2-S19.
3. Ola MS, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis. Mol Cell Biochem 2011; 351: 41-58.
4. Leibowitz B, Yu J. Mitochondrial signaling in cell death via the Bcl-2 family. Cancer Biol Ther 2010; 9: 417-422.
5. Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T et al. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX-and BAK-mediated mitochondrial apoptosis. Mol Cell 2001; 8: 705-711.
6. Cragg MS, Harris C, Strasser A, Scott CL. Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. Nat Rev Cancer 2009; 9: 321-326.
7. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-681.
8. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006; 10: 375-388.
9. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006; 10: 389-399.
10. Zhu H, Yang W, He LJ, Ding WJ, Zheng L, Liao SD et al. Upregulating Noxa by ER stress, celastrol exerts synergistic anti-cancer activity in combination with ABT-737 in human hepatocellular carcinoma cells. PLoS One 2012; 7: e52333.
11. Sun XP, Zhang X, He C, Qiao H, Jiang X, Jiang H et al. ABT-737 synergizes with arsenic trioxide to induce apoptosis of gastric carcinoma cells in vitro and in vivo. J Int Med Res 2012; 40: 1251-1264.
12. Zhang S, Li G, Ma X, Wang Y, Liu G, Feng L et al. Norcantharidin enhances ABT-737-induced apoptosis in hepatocellular carcinoma cells by transcriptional repression of Mcl-1. Cell Signal 2012; 24: 1803-1809.
13. Doi K, Li R, Sung SS, Wu H, Liu Y, Manieri W et al. Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation. J Biol Chem 2012; 287: 10224-10235.
14. Yin S, Dong Y, Li J, Fan L, Wang L, Lu J et al. Methylseleninic acid potentiates multiple types of cancer cells to ABT-737-induced apoptosis by targeting Mcl-1 and Bad. Apoptosis 2012; 17: 388-399.
15. Song JH, Kraft AS. Pim kinase inhibitors sensitize prostate cancer cells to apoptosis triggered by Bcl-2 family inhibitor ABT-737. Cancer Res 2012; 72: 294-303.
16. Kim JY, Kim DH, Jeong HG. Inhibitory effect of the coffee diterpene kahweol on carrageenan-induced inflammation in rats. Biofactors 2006; 26: 17-28.
17. Kim JY, Jung KS, Jeong HG. Suppressive effects of the kahweol and cafestol on cyclooxygenase-2 expression in macrophages. FEBS Lett 2004; 569: 321-326.
18. Cardenas C, Quesada AR, Medina MA. Anti-angiogenic and anti-inflammatory properties of kahweol, a coffee diterpene. PLoS One 2011; 6: e23407.
19. Cavin C, Holzhaeuser D, Scharf G, Constable A, Huber WW, Schilter B. Cafestol and kahweol, two coffee specific diterpenes with anticarcinogenic activity. Food Chem Toxicol 2002; 40: 1155-1163.
20. Tao KS, Wang W, Wang L, Cao DY, Li YQ, Wu SX et al. The multifaceted mechanisms for coffee's anti-tumorigenic effect on liver. Med Hypotheses 2008; 71: 730-736.
21. Lee KA, Chae JI, Shim JH. Natural diterpenes from coffee, cafestol and kahweol induce apoptosis through regulation of specificity protein 1 expression in human malignant pleural mesothelioma. J Biomed Sci 2012; 19: 60.
22. Choi MJ, Park EJ, Oh JH, Min KJ, Yang ES, Kim YH et al. Cafestol, a coffee-specific diterpene, induces apoptosis in renal carcinoma Caki cells through down-regulation of anti-apoptotic proteins and Akt phosphorylation. Chem Biol Interact 2011; 190: 102-108.
23. Mazumder S, Choudhary GS, Al-Harbi S, Almasan A. Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells. Cancer Res 2012; 72: 3069-3079.
24. Zhong Q, Gao W, Du F, Wang X. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 2005; 121: 1085-1095.
25. Groll M, Huber R. Substrate access and processing by the 20S proteasome core particle. Int J Biochem Cell Biol 2003; 35: 606-616.
26. Chauhan D, Velankar M, Brahmandam M, Hideshima T, Podar K, Richardson P et al. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene 2007; 26: 2374-2380.
27. Vogler M, Dinsdale D, Sun XM, Young KW, Butterworth M, Nicotera P et al. A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells. Cell Death Differ 2008; 15: 820-830.
28. Hann CL, Daniel VC, Sugar EA, Dobromilskaya I, Murphy SC, Cope L et al. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res 2008; 68: 2321-2328.
29. Kang MH, Wan Z, Kang YH, Sposto R, Reynolds CP. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. J Natl Cancer Inst 2008; 100: 580-595.
30. Russo M, Spagnuolo C, Volpe S, Tedesco I, Bilotto S, Russo GL. ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation. Biochem Pharmacol 2013; 85: 927-936.
31. Zhang C, Cai TY, Zhu H, Yang LQ, Jiang H, Dong XW et al. Synergistic antitumor activity of gemcitabine and ABT-737 in vitro and in vivo through disrupting the interaction of USP9X and Mcl-1. Mol Cancer Ther 2011; 10: 1264-1275.
32. Xu H, Krystal GW. Actinomycin D decreases Mcl-1 expression and acts synergistically with ABT-737 against small cell lung cancer cell lines. Clin Cancer Res 2010; 16: 4392-4400.
33. Jona A, Khaskhely N, Buglio D, Shafer JA, Derenzini E, Bollard CM et al. The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors. Exp Hematol 2011; 39: 1007-1017 e1001.
34. Strasser A, Cory S, Adams JM. Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J 2011; 30: 3667-3683.
35. Nijhawan D, Fang M, Traer E, Zhong Q, Gao W, Du F et al. Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev 2003; 17: 1475-1486.
36. Ding Q, He X, Hsu JM, Xia W, Chen CT, Li LY et al. Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol Cell Biol 2007; 27: 4006-4017.
37. Weng C, Li Y, Xu D, Shi Y, Tang H. Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells. J Biol Chem 2005; 280: 10491-10500.
38. Clohessy JG, Zhuang J, Brady HJ. Characterisation of Mcl-1 cleavage during apoptosis of haematopoietic cells. Br J Haematol 2004; 125: 655-665.
39. Han J, Goldstein LA, Gastman BR, Froelich CJ, Yin XM, Rabinowich H. Degradation of Mcl-1 by granzyme B: implications for Bim-mediated mitochondrial apoptotic events. J Biol Chem 2004; 279: 22020-22029.
40. Liao A, Broeg K, Fox T, Tan SF, Watters R, Shah MV et al. Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia. Blood 2011; 118: 2793-2800.
41. Tallarida RJ. Drug synergism: its detection and applications. J Pharmacol Exp Ther 2001; 298: 865-872.
42. Stewart DP, Koss B, Bathina M, Perciavalle RM, Bisanz K, Opferman JT. Ubiquitin-independent degradation of antiapoptotic MCL-1. Mol Cell Biol 2010; 30: 3099-3110.